Literature DB >> 23715647

MLH1 as a direct target of MiR-155 and a potential predictor of favorable prognosis in pancreatic cancer.

Wen-Jing Liu1, Yu-Pei Zhao, Tai-Ping Zhang, Li Zhou, Quan-Cai Cui, Wei-Xun Zhou, Lei You, Ge Chen, Hong Shu.   

Abstract

BACKGROUND: The regulation of Mut L homologue 1 (MLH1) expression by microRNA (miR)-155 and its prognostic significance in pancreatic cancer (PC) remain to be elucidated. This study aimed to address the issues.
METHODS: MiR-155 mimics and inhibitor were transfected to PC cell lines, Panc-1 and Capan-1. Expression of MLH1 was subsequently evaluated. Then, luciferase activity was detected after miR-155 mimics and pRL-TK plasmids containing wild-type and mutant 3'UTRs of MLH1 mRNA were co-transfected. Finally, immunohistochemical staining for MLH1 was performed in PC samples.
RESULTS: Transfection of miR-155 mimics and inhibitor led to reversely altered protein expressions of miR-155 and MLH1, whereas the corresponding mRNA expressions were similar. A significant decrease in luciferase activity in the cells transfected with the wild-type pRL-TK plasmid was shown in contrast to those transfected with the mutant one. In addition, MLH1 was less expressed in tumor than in para-tumor tissues of PC. Extensive MLH1 expression was significantly associated with favorable differentiation and less lymph node metastasis. MLH1 expression was found to be a prognosticator in univariate analysis, and being of marginally significant impact in multivariate test.
CONCLUSIONS: MLH1 might serve as a direct target of miR-155 and a potential prognosis predictor in PC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23715647     DOI: 10.1007/s11605-013-2230-5

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  35 in total

Review 1.  Pancreatic cancer.

Authors:  Manuel Hidalgo
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

2.  Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer.

Authors:  Shadan Ali; Sanjeev Banerjee; Farah Logna; Bin Bao; Philip A Philip; Murray Korc; Fazlul H Sarkar
Journal:  J Cell Physiol       Date:  2012-10       Impact factor: 6.384

3.  Modulation of mismatch repair and genomic stability by miR-155.

Authors:  Nicola Valeri; Pierluigi Gasparini; Muller Fabbri; Chiara Braconi; Angelo Veronese; Francesca Lovat; Brett Adair; Ivan Vannini; Francesca Fanini; Arianna Bottoni; Stefan Costinean; Sukhinder K Sandhu; Gerard J Nuovo; Hansjuerg Alder; Roberta Gafa; Federica Calore; Manuela Ferracin; Giovanni Lanza; Stefano Volinia; Massimo Negrini; Michael A McIlhatton; Dino Amadori; Richard Fishel; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

4.  Loss of hMLH1 expression is associated with less aggressive clinicopathological features in sporadic endometrioid endometrial adenocarcinoma.

Authors:  Woong Ju; Han Moie Park; Shi Nae Lee; Sun Hee Sung; Seung Cheol Kim
Journal:  J Obstet Gynaecol Res       Date:  2006-10       Impact factor: 1.730

5.  Frequent alterations of the candidate genes hMLH1, ITGA9 and RBSP3 in early dysplastic lesions of head and neck: clinical and prognostic significance.

Authors:  Amlan Ghosh; Susmita Ghosh; Guru Prasad Maiti; Mohammad Golam Sabbir; Eugene R Zabarovsky; Anup Roy; Susanta Roychoudhury; Chinmay Kumar Panda
Journal:  Cancer Sci       Date:  2010-02-04       Impact factor: 6.716

6.  Clinical and pathologic prognostic factors for curative resection for pancreatic cancer.

Authors:  M V Perini; A L Montagnini; J Jukemura; S Penteado; E E Abdo; R Patzina; I Cecconello; J E M Cunha
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

7.  Human mismatch repair gene, MLH1, is transcriptionally repressed by the hypoxia-inducible transcription factors, DEC1 and DEC2.

Authors:  H Nakamura; K Tanimoto; K Hiyama; M Yunokawa; T Kawamoto; Y Kato; K Yoshiga; L Poellinger; E Hiyama; M Nishiyama
Journal:  Oncogene       Date:  2008-03-17       Impact factor: 9.867

8.  Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development.

Authors:  Meritxell Gironella; Mylène Seux; Min-Jue Xie; Carla Cano; Richard Tomasini; Julien Gommeaux; Stephane Garcia; Jonathan Nowak; Man Lung Yeung; Kuan-Teh Jeang; Amandine Chaix; Ladan Fazli; Yoshiharu Motoo; Qing Wang; Palma Rocchi; Antonio Russo; Martin Gleave; Jean-Charles Dagorn; Juan L Iovanna; Alice Carrier; Marie-Josèphe Pébusque; Nelson J Dusetti
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-02       Impact factor: 11.205

9.  Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer.

Authors:  Takao Ide; Yoshihiko Kitajima; Kazuma Ohtaka; Mayumi Mitsuno; Yuji Nakafusa; Kohji Miyazaki
Journal:  Oncol Rep       Date:  2008-06       Impact factor: 3.906

10.  Expression of the DNA mismatch repair proteins (hMLH1 and hMSH2) in infiltrating pancreatic cancer and its relation to some phenotypic features.

Authors:  Romana Tomaszewska; Krzysztof Okoń; Jerzy Stachura
Journal:  Pol J Pathol       Date:  2003       Impact factor: 1.072

View more
  20 in total

1.  MicroRNA-155 promotes apoptosis in SKOV3, A2780, and primary cultured ovarian cancer cells.

Authors:  Wei Chen; Liuxuan Huang; Chenjun Hao; Wenshu Zeng; Xu Luo; Xiaodi Li; Longshu Zhou; Songshan Jiang; Zheng Chen; Yuanli He
Journal:  Tumour Biol       Date:  2016-01-15

2.  Up-regulated miR-155-5p promotes cell proliferation, invasion and metastasis in colorectal carcinoma.

Authors:  Yan-Li Qu; Hai-Feng Wang; Zhen-Qiang Sun; Yong Tang; Xiao-Na Han; Xian-Bo Yu; Kun Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

Review 3.  MicroRNA in pancreatic cancer.

Authors:  Keiichi Yonemori; Hiroshi Kurahara; Kosei Maemura; Shoji Natsugoe
Journal:  J Hum Genet       Date:  2016-06-02       Impact factor: 3.172

4.  Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704.

Authors:  Yaacov R Lawrence; Jennifer Moughan; Anthony M Magliocco; Alexander C Klimowicz; William F Regine; Rex B Mowat; Thomas A DiPetrillo; William Small; Jeffry P Simko; Talia Golan; Kathryn A Winter; Chandan Guha; Christopher H Crane; Adam P Dicker
Journal:  Cancer       Date:  2017-10-20       Impact factor: 6.860

5.  Differential Expression of MicroRNAs in Tissues and Plasma Co-exists as a Biomarker for Pancreatic Cancer.

Authors:  Shadan Ali; Hala Dubaybo; Randall E Brand; Fazlul H Sarkar
Journal:  J Cancer Sci Ther       Date:  2015

6.  MicroRNA-155 expression is independently predictive of outcome in chordoma.

Authors:  Eiji Osaka; Andrew D Kelly; Dimitrios Spentzos; Edwin Choy; Xiaoqian Yang; Jacson K Shen; Pei Yang; Henry J Mankin; Francis J Hornicek; Zhenfeng Duan
Journal:  Oncotarget       Date:  2015-04-20

Review 7.  The miRacle in Pancreatic Cancer by miRNAs: Tiny Angels or Devils in Disease Progression.

Authors:  Zuhair Hawa; Inamul Haque; Arnab Ghosh; Snigdha Banerjee; LaCoiya Harris; Sushanta K Banerjee
Journal:  Int J Mol Sci       Date:  2016-05-26       Impact factor: 5.923

Review 8.  MicroRNA Targeted Therapeutic Approach for Pancreatic Cancer.

Authors:  Yiwei Li; Fazlul H Sarkar
Journal:  Int J Biol Sci       Date:  2016-01-28       Impact factor: 6.580

Review 9.  Pancreatic Cancer, A Mis-interpreter of the Epigenetic Language.

Authors:  Eriko Iguchi; Stephanie L Safgren; David L Marks; Rachel L Olson; Martin E Fernandez-Zapico
Journal:  Yale J Biol Med       Date:  2016-12-23

10.  Direct quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer.

Authors:  Xin Zhang; Yanli Zhang; Xinfeng Liu; Aiju Fang; Jinfeng Wang; Yongmei Yang; Lili Wang; Lutao Du; Chuanxin Wang
Journal:  Oncotarget       Date:  2016-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.